Fulcrum therapeutics reports recent business highlights and second quarter 2021 financial results

– reported positive interim results from ongoing phase 1 trial in healthy adult volunteers with ftx-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology –

FULC Ratings Summary

FULC Quant Ranking